OWLT

Owlet, Inc. (OWLT) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Owlet, Inc. is a pediatric health platform offering FDA-cleared wearable monitors and the Owlet360 subscription service. The company is classified as a smaller reporting company and a non-accelerated filer. As of May 6, 2026, there were 29,001,168 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 6.4% to $22.5 million. Hardware revenue declined 4.5% ($19.8M) due to a large retail partner tightening inventory supply, partially offset by a 569.3% surge in subscription revenue ($2.7M) driven by higher subscriber counts and ARPU.
• Profitability: The company returned to a net loss of $3.3 million compared to a net income of $3.0 million in Q1 2025. This shift was primarily driven by a $4.1 million decrease in the non-cash "Common stock warrant liability adjustment" gain (from $6.7M to $2.6M) and increased operating expenses.
• Operating Expenses: Total operating expenses rose 26.7% to $17.7 million. General and Administrative (G&A) expenses increased 31.2% due to higher stock-based compensation ($1.4M increase) and headcount costs. R&D expenses grew 36.3% due to personnel and regulatory testing costs.
• Liquidity: Cash and cash equivalents increased significantly to $35.5 million, bolstered by a $32.1 million equity offering in October 2025. However, the company continues to burn cash, with operating cash outflows of $5.0 million.
• Debt: Total debt increased to $18.8 million. Borrowings under the ABL Line of Credit rose to $13.4 million (up from $6.9 million), while the WTI Term Loan principal decreased slightly to $6.3 million.

Guidance, Outlook, Risks, and Unusual Items

• Executive Transition: In a subsequent event (April 2026), Kurt Workman was appointed President and CEO, succeeding Jonathan Harris. Harris received accelerated vesting of equity awards valued at approximately $2.6 million.
• Legal Settlements: The company reached settlements for the Butala and Cherian class actions. A total of $5.25 million was paid into escrow (partially covered by insurance) and is classified as restricted cash pending final court approval. A derivative suit settlement of $675,000 is also pending final approval.
• Tariff Relief: A February 2026 Supreme Court ruling invalidated certain tariffs. The company is evaluating potential refunds of previously paid duties, which could be material, but has not recognized a receivable yet.
• Going Concern: Management believes existing cash, cash flows, and credit lines are sufficient for the next 12 months. However, the company has a history of losses and an accumulated deficit of $311.2 million.
• Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses in the control environment, segregation of duties, inventory accounting, and IT general controls. Remediation is ongoing.

Investor Verification Checklist

• Warrant Liability Volatility: Verify the sensitivity of the "Common stock warrant liability adjustment" to stock price fluctuations, as this non-cash item significantly distorts GAAP net income/loss.
• Debt Covenants: Confirm compliance with the ABL Line of Credit liquidity covenant (minimum $4.0M liquidity) and EBITDA covenants, especially given the recent increase in borrowings.
• Legal Escrow Status: Monitor the final court approval status of the $5.25M litigation settlement escrow to determine if funds will be released or if additional liabilities may arise.
• Internal Control Remediation: Assess the timeline and progress of remediation for the identified material weaknesses in financial reporting and IT controls.
• Subscription Churn: Evaluate the sustainability of the 569% subscription revenue growth and monitor subscriber churn rates, as this is a key driver of future margin expansion.